FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Change Labeling for Hormonally Active Contraceptives: Petition

[ Price : $8.95]

The Contraceptive Study Group submits a second petition to FDA seeking changes in labeling for hormonally active contraceptives to...

FDA Extends Molgramostim BLA Review for 3 Months

[ Price : $8.95]

FDA extends until 11/22 its review of a Savara BLA for molgramostim to treat autoimmune pulmonary alveolar proteinosis.

FDAs No. 2 Brenner May Move to CDC Senior Role

[ Price : $8.95]

The Trump Administration looks to move FDA principal deputy commissioner Sarah Brenner to a senior leadership role at the CDC.

FDA Updates Compliance Program for Biologic Drug Manufacturers

[ Price : $8.95]

FDA issues an updated compliance program that standardizes how inspectors evaluate manufacturing facilities tied to biologic drug ...

2 CDER Postmarketing MAPPS Out

[ Price : $8.95]

CDER issues two revised Manuals of Policies and Procedures relating to developing and communicating postmarketing requirements and...

FDA Panel Meeting to Mull Adding Peptides to Compounding List

[ Price : $8.95]

FDA plans a 7/23-24 Pharmacy Compounding Advisory Committee meeting to discuss adding certain peptides to the agencys bulk drugs f...

Quality, Data Integrity Issues Flagged at Indian API Maker Hikal

[ Price : $8.95]

FDA cites significant manufacturing and data integrity deficiencies at Hikal Limited following a 2/2025 inspection of the companys...

Traveres Filspari Approved for Rare Kidney Disease FSGS

[ Price : $8.95]

FDA approves Travere Therapeutics Filspari (sparsentan), a therapy for treating patients with Focal Segmental Glomerulosclerosis.

Bioanalytical Method Validation for Biomarkers Guidance

[ Price : $8.95]

FDA publishes a guidance titled "Bioanalytical Method Validation for Biomarkers to help sponsors to validate bioanalytical methods...

CGMP Violations Found at Medical Products Laboratories

[ Price : $8.95]

FDA warns Philadelphia, PA-based Medical Products Laboratories about CGMP violations in its manufacturing of unapproved new drugs.